Table 2.
Association of baseline eGFR and UACR with the risk for cognitive impairment
| Baseline Kidney Markers | Probable Dementia | MCI | Probable Dementia or MCI | |||
|---|---|---|---|---|---|---|
| Cases per 1000 PY | Adjusted HR (95% CI)a | Cases per 1000 PY | Adjusted HR (95% CI)a | Cases per 1000 PY | Adjusted HR (95% CI)a | |
| eGFR, ml/min per 1.73 m2 | ||||||
| eGFR<60 | ||||||
| Yes (n=2385) | 13.0 | 1.04 (0.80 to 1.36) | 21.9 | 0.98 (0.80 to 1.18) | 31.1 | 1.02 (0.86 to 1.20) |
| No (n=6178) | 12.1 | Referent | 14.5 | Referent | 18.9 | Referent |
| UACR, mg/g | ||||||
| UACR≥30 | ||||||
| Yes (n=1539) | 12.4 | 1.24 (0.93 to 1.66) | 22.3 | 1.11 (0.90 to 1.38) | 31.4 | 1.05 (0.88 to 1.26) |
| No (n=6627) | 7.1 | Referent | 15.3 | Referent | 20.3 | Referent |
PY, person-years.
a
Adjusted HR on the basis of the Cox proportional hazards regression model with the baseline hazard function stratified by clinic site. Model covariates include treatment assignment, age, sex, race, education, systolic BP, diastolic BP, angiotensin-converting enzyme inhibitor use, angiotensin receptor blocker use, smoking status, alcohol use, body mass index, Montreal Cognitive Assessment score, Framingham 10-year cardiovascular risk score, Medical and Mental Comorbidity Index, and UACR (in eGFR model) or eGFR (in UACR model).